Pancreas

Gastroenterology. 2022;162(3):772–85.e4

Overbeek KA, Goggins MG, Dbouk M, Levink IJM, Koopmann BDM, Chuidian M, Konings ICAW, Paiella S, Earl J, Fockens P, Gress TM, Ausems MGEM, Poley JW, Thosani NC, Half E, Lachter J, Stoffel EM, Kwon RS, Stoita A, Kastrinos F, Lucas AL, Syngal S, Brand RE, Chak A, Carrato A, Vleggaar FP, Bartsch DK, van Hooft JE, Cahen DL, Canto MI, Bruno MJ; International Cancer of the Pancreas Screening Consortium

Timeline of development of pancreatic cancer and implications for successful early detection in high-risk individuals


Background and aims: To successfully implement imaging-based pancreatic cancer (PC) surveillance, understanding the timeline and morphologic features of neoplastic progression is key. The authors aimed to investigate the progression to neoplasia from serial prediagnostic pancreatic imaging tests in high-risk individuals and identify factors associated with successful early detection.
Methods: They retrospectively examined the development of pancreatic abnormalities in high-risk individuals who were diagnosed with PC or underwent pancreatic surgery, or both, in 16 international surveillance programs.
Results: Of 2552 high-risk individuals under surveillance, 28 (1%) developed neoplastic progression to PC or high-grade dysplasia during a median follow-up of 29 months after baseline (interquartile range [IQR], 40 months). Of these, 13 of 28 (46%) presented with a new lesion (median size, 15 mm; range 7–57 mm), a median of 11 months (IQR, 8; range 3–17 months) after a prior examination, by which time 10 of 13 (77%) had progressed beyond the pancreas. The remaining 15 of 28 (54%) had neoplastic progression in a previously detected lesion (12 originally cystic, 2 indeterminate, 1 solid), and 11 (73%) had PC progressed beyond the pancreas. The 12 patients with cysts had been monitored for 21 months (IQR, 15 months) and had a median growth of 5 mm/year (IQR, 8 mm/year). Successful early detection (as high-grade dysplasia or PC confined to the pancreas) was associated with resection of cystic lesions (vs. solid or indeterminate lesions (odds ratio [OR] = 5.388, 95% confidence interval [CI]: 1.525–19.029) and small lesions (OR = 0.890/mm, 95% CI: 0.812–0.976/mm).

Conclusions: In nearly half of high-risk individuals developing high-grade dysplasia or pancreatic cancer, no prior lesions are detected by imaging, yet they present at an advanced stage. Progression can occur before the next scheduled annual examination. More sensitive diagnostic tools or a different management strategy for rapidly growing cysts are needed.

Dr. K.A. Overbeek, Department of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands,
E-Mail: k.overbeek@erasmusmc.nl

DOI: DOI: 10.1053/j.gastro.2021.10.014

Back to overview

this could be of interest:

Changes in metabolic syndrome status are associated with altered risk of pancreatic cancer: A nationwide cohort study

Gastroenterology. 2022;162(2):509–20.e7

Late-stage pancreatic cancer detected during high-risk individual surveillance: A systematic review and meta-analysis

Gastroenterology. 2022;162(3):786–98

More articles on the topic